Status:
UNKNOWN
Dietary Intervention in Follicular Lymphoma
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
University of Oslo
Conditions:
Follicular Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A dietary intervention study in patients with Follicular Lymphoma (FL) Stage III/IV to assess the ability of several dietary factors to induce apoptosis, inhibit cell proliferation and modulate tumor ...
Detailed Description
Dietary factors plays an important role in the prevention of several diseases. The cardiovascular disease mortality have dropped dramatically the last 20 years, but the relative death rates from cance...
Eligibility Criteria
Inclusion
- Age 18 years or more.
- Permanent address in Norway, located in health region south or east. People living outside these areas in other health regions in Norway may be able to participate but after individual evaluation.
- Histologically verified follicular lymphoma grade I or II without clinical signs of transformation to aggressive lymphoma.
- Stage III/IV.
- Previously untreated or at least 1 year since rituximab treatment or 6 months since cytotoxic chemotherapy.
- Not scheduled for disease specific treatment for the next 3 months.
- At least one pathological superficial lymph node available for ultrasound guided biopsy.
- Cytologically and/or immunocytologically compatible with follicular lymphoma.
- Women with childbearing potential, only with use of safe contraceptives
Exclusion
- Gross abnormalities in blood samples. (Hematologic values Hgb\< 10, leukocytes\< 2,5, trombocytes \<100, liver enzymes (ALAT,ASAT,GT,ALP) \> 2,5 x upper normal values,bilirubin \>35 creatinine \>130)
- Other serious medical illness (unstable cardiovascular disease, unstable pulmonary disease, uncontrolled diabetes, autoimmunity, chronic infection or other active cancer).
- Use of NSAID, ASA the last two weeks prior to enrollment.
- Use of systemic corticosteroids the last two months prior to enrollment.
- Regular use of anticoagulants as LMW Heparin or warfarin.
- Use of carbamazepin, nifedipin and other drugs metabolized with CYP 3A4 where interaction might cause hazardous side effects which cannot be controlled with serum measurements or organ function monitoring.
- Inclusion in another clinical trial which involves medication or nutritional supplements.
- Use of complementary medicine/alternative medicine which includes high dose\* vitamins or antioxidants/nutritional supplements 2 weeks prior to sampling procedures .
- Regularly use of omega 3 fatty acids more than 1g / day
- History of serious or unstable medical or psychiatric disorder.
- History of heavy alcohol consumption \> 3 units / day.
- Pregnancy
- Individuals judged by the clinical investigator to be unable to follow instructions and procedures of the study.
- (\*high dose is defined as vitamins or antioxidant supplements exceeding what is present in regular multi-vitamin supplements covering regular RDAs)
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00455416
Start Date
April 1 2007
End Date
December 1 2009
Last Update
May 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RRHF RIkshospitalet Radiumhospitalet HF
Montebello, Oslo County, Norway, 0310